Trademark: 88912457
Word
PREVADDUCT
Status
Dead
Status Code
606
Status Date
Monday, December 18, 2023
Serial Number
88912457
Mark Type
4000
Filing Date
Tuesday, May 12, 2020
Published for Opposition
Tuesday, September 15, 2020
Abandoned Date
Monday, December 18, 2023

Trademark Owner History
Adduct Pharmaceutical, Inc. - Owner At Publication

Classifications
5 Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment and prevention of oxidative damage; Pharmaceutical preparations for the treatment and prevention of chronic inflammation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical products and preparations to prevent swelling in the legs; Preparation for the relief of pain

Trademark Events
Dec 18, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Dec 18, 2023
Abandonment - No Use Statement Filed
May 12, 2023
Notice Of Approval Of Extension Request E-Mailed
May 11, 2023
Sou Extension 5 Granted
May 7, 2023
Sou Extension 5 Filed
May 11, 2023
Case Assigned To Intent To Use Paralegal
May 7, 2023
Sou Teas Extension Received
Nov 12, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 10, 2022
Sou Extension 4 Granted
Nov 10, 2022
Sou Extension 4 Filed
Nov 10, 2022
Sou Teas Extension Received
May 10, 2022
Notice Of Approval Of Extension Request E-Mailed
May 8, 2022
Sou Extension 3 Granted
May 8, 2022
Sou Extension 3 Filed
May 8, 2022
Sou Teas Extension Received
Nov 9, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 5, 2021
Sou Extension 2 Granted
Nov 5, 2021
Sou Extension 2 Filed
Nov 5, 2021
Sou Teas Extension Received
May 12, 2021
Notice Of Approval Of Extension Request E-Mailed
May 10, 2021
Sou Extension 1 Granted
May 10, 2021
Sou Extension 1 Filed
May 10, 2021
Sou Teas Extension Received
Nov 10, 2020
Noa E-Mailed - Sou Required From Applicant
Sep 15, 2020
Official Gazette Publication Confirmation E-Mailed
Sep 15, 2020
Published For Opposition
Aug 26, 2020
Notification Of Notice Of Publication E-Mailed
Aug 11, 2020
Approved For Pub - Principal Register
Aug 9, 2020
Assigned To Examiner
May 26, 2020
New Application Office Supplied Data Entered
May 15, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24